Granza Bio, Advancing Therapeutic Delivery using Precision Shells has raised $7M.14Mn in Seed Funding round led by Felicis and Refactor.Granza Bio intends to use the money to grow its operations and development efforts.
Read also – [Funding News] OH-based Tembo Raises $14M in Series A Funding
Other participation from Y Combinator, Metaplanet, Zeno Ventures, Ritual Capital, Pioneer Fund, Oxford Angel Fund, North South Ventures, Richard Aberman, JJ Fliegelman, Eric Migicovsky, Eric Eldon, Eli Brown, Eoghan Mccabe, Benjamin Bryant, Yotam Rosenbaum, Will Olsen and Joel Meyer.
Read also – Thoma Bravo Completes Acquisition of Everbridge
Felicis back founders building iconic companies that transcend boundaries: we partner around the world, across sectors, and at various stages, primarily before success is obvious. Felicis also invest directly in founders’ growth by committing 1% on top of every first check we write towards personalized executive coaching, therapy and more.
Refactor invests in seed-stage hard tech companies that create technologies to enhance planetary and human health, radically upending traditionally regulated industries. This is refactoring at its essence—creating more accessible, efficient, and scalable solutions. Refactor supports founders who go beyond obstacles and expectations, so that we can build a happier, healthier, and more habitable world.
About Granza Bio
Founded in 2023, Granza Bio is a biotechnology company developing a novel delivery “shell” platform to direct therapeutic cargo to specific tissues. For their lead candidate, Granza Bio is leveraging the discovery of the immune system’s powerful suite of weapons, “attack particles”. Utilizing their advanced delivery platform, they aim to target these “attack particles” against a range of diseases such as cancer, autoimmune disorders, and infections.
